Join

Compare · NVO vs PLRX

NVO vs PLRX

Side-by-side comparison of Novo Nordisk A/S (NVO) and Pliant Therapeutics Inc. (PLRX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and PLRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $222.81B, about 3129.0x PLRX ($71.2M).
  • Over the past year, NVO is down 22.5% and PLRX is down 21.0% - PLRX leads by 1.6 points.
  • PLRX has been more active in the news (6 items in the past 4 weeks vs 4 for NVO).
  • NVO has more recent analyst coverage (25 ratings vs 24 for PLRX).
PerformanceNVO-22.53%PLRX-20.96%
2025-07-21+0.00%2026-07-17
MetricNVOPLRX
Company
Novo Nordisk A/S
Pliant Therapeutics Inc.
Price
$50.31-2.25%
$1.15+5.50%
Market cap
$222.81B
$71.2M
1M return
+15.47%
-2.95%
1Y return
-22.53%
-20.96%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
4
6
Recent ratings
25
24
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

PLRX

Pliant Therapeutics Inc.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.

Latest NVO

Latest PLRX